Systemic mesenchymal stem cells reduce growth rate of cisplatin-resistant ovarian cancer.
Epithelial ovarian cancer is one of the most malignant cancers in women and resistant to chemotherapy is the major obstacle for the five-year survival rate. Cisplatin is one of the effective anticancer drug used in the ovarian cancer. To find a good strategy to cure the tumors which is resistant to cisplatin, the cisplatin-resistant 3SKOV3 cells were selected from SKOV-3 ovarian cancer cells. Furthermore, the isolated mesenchymal stem cells were infused systemically to try to cure the transplanted tumor induced by 3SKOV3 cells in nude mice. The morphology and cell membrane CD44 expression were investigated by microscope and flow cytometry. The biological behaviors of resistant 3SKOV3 and its parental SKOV3 cells, including proliferation, adhesion, and cell cycle were determined by CCK8, absorbance assay and FCM methods. The transplanted tumors were set up in nude mice with 3SKOV3 cells injection. The growth rate of transplanted tumors was detected following with MSCs injection. The 3SKOV3 cells have different morphologic manifestation and expressed high level of CD44 molecule. At the same time, 3SKOV3 cells have less adhesion ability and less S-phase ratio. The isolated MSCs from bone marrow could inhibit the growth of transplanted tumor via systemic injection. The cisplatin-resistant 3SKOV3 cells have the different biological behaviors as its parental SKOV3 cells. The present study indicated that systemic MSCs have the therapeutic role on ovarian cancer. However, further investigations are in progress to elucidate the underlying mechanism.
Department of Gynecology, Obstetrics & Gynecology Hospital, Fudan University 419 Fangxie Rd, Shanghai, 200011, PR China ; Department of Obstetrics and Gynecology, Shangyu City Hospital 517 Shimin Blvd Baiguan St, Shangyu, Zhejiang Province, 312000, PR China.
Pengfei
P
Zhu
Mo
M
Chen
Li
L
Wang
Yanxia
Y
Ning
Jie
J
Liang
Hao
H
Zhang
Congjian
C
Xu
Sifeng
S
Chen
Liangqing
L
Yao
D000818:Animals; D000970:Antineoplastic Agents; D002448:Cell Adhesion; D002453:Cell Cycle; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002945:Cisplatin; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D051379:Mice; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D047368:Tumor Burden; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; C497483:CD44 protein, human; D018960:Hyaluronan Receptors; D002945:Cisplatin
Cisplatin; mesenchymal stem cells; nude mice; ovarian cancer; resistance